The observation that there were reductions in HRH3 expression in the brains of many of the patients replicated the work of Renthal et al. from the occipital cortex (Renthal, Boxer et al. 2018), suggesting that the H3 receptor might serve as a novel, druggable therapeutic target in RTT. This evidence concerns the gene HRH3 and Rett syndrome.